Premium
Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma
Author(s) -
FernándezdeMisa R.,
HernándezMachín B.,
Combalía A.,
García Muret M.P.,
Servitje O.,
Muniesa C.,
Gallardo F.,
Pujol R.M.,
Martí R.M.,
OrtizBrugués A.,
MaroñasJiménez L.,
OrtizRomero P.L.,
Blanch Rius L.,
Izu R.,
Román C.,
Cañueto J.,
Blanes M.,
Morillo M.,
Bastida J.,
Peñate Y.,
Pérez Gala S.,
Espinosa Lara P.,
Pérez Gil A.,
Estrach T.
Publication year - 2020
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.16006
Subject(s) - medicine , radiation therapy , lymphoma , chemotherapy , surgery , retrospective cohort study , tumor progression , gastroenterology , cancer
Background Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma ( PCALCL ) are lacking. Objective To identify prognostic factors for specific survival in patients with PCALCL . Methods Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed. Results One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1‐3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first‐line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5‐year specific survival ( SSV ) reached 93%; 97% for T1 patients and 84% for T2/T3 patients ( P = 0.031). Five‐year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% ( P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI : 51–155 months); for patients without nodal progression, estimated SSV did not reach the median ( P < 0.001). Nodal progression was an independent predictive parameter for shorter survival ( P = 0.011). Conclusion Multiple cutaneous lesions at presentation, early skin relapse and nodal progression portrait worse prognosis in patients with PCALCL .